Nevirapine Tablets

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus (HIV-1). Nevirapine directly binds to the reverse transcriptase (RT) of HIV-1 and blocks both RNA-dependent and DNA-dependent DNA polymerase activity by cleaving the catalytic end of the enzyme. Nevirapine does not compete with substrates or nucleoside triphosphates.

The main ingredient of this product is nevirapine, whose chemical name is 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2#39;,3#39;-e][1,4]diazepine-6-one

This product is suitable for the treatment of HIV-1 infection and should be used in combination with other anti-HIV-1 drugs. It can be used alone to prevent mother-to-child transmission.

Adults: Oral, 200 mg once a day for 14 consecutive days (this introduction period can reduce the incidence of rash); then change to 200 mg twice a day, and use at least two other anti-HIV-1 drugs at the same time. Children: The recommended oral dose for children aged 2 months to 8 years (excluding 8 years) is 4 mg/kg once a day for the first 14 days; then change to 7 mg/kg twice a day. The recommended dose for children aged 8 years and above is 4 mg/kg once a day for the first 14 days; then change to 4 mg/kg twice a day. The total daily dose for any patient should not exceed 400 mg. Patients should be informed of the necessity of taking nevirapine daily according to the prescribed dose. If a dose is missed, the patient should take the next dose as soon as possible, but do not double it. If the patient stops taking nevirapine for more than seven days, it should be restarted according to the principle of dosing, that is, 200 mg of the drug, once a day, and then 200 mg twice a day.

Rash, abnormal liver function, fatigue, fever, headache, lethargy, gastrointestinal adverse reactions and myalgia. Severe hepatitis/liver failure and allergic reactions.

Pregnant women should use it with caution and breastfeeding women should not use it.

Precautions during pregnancy and lactation: Use with caution in pregnant women and prohibited for use in lactating women.

Nevirapine is an inducer of hepatic cytochrome P450 metabolizing enzymes and can reduce the plasma concentrations of drugs that are mainly metabolized by CYP3A and CYP2B. Therefore, if a patient is receiving a stable dose of a drug metabolized by CYP3A or CYP2B, the dose of the former needs to be adjusted if this product is co-administered.

Sealed storage

0.2 g

Matrix Laboratories (Xiamen) Ltd.

• Founded in:

  2002-09-06

• Address:

  No. 6, Yangtai Road, Xinyang Industrial Zone, Haicang District, Xiamen

• Tax NO.:

  91350200155018328Q

• Registered Funds:

  178.116658 million yuan

• Email:

  Log in to view